The Future

of Immunotherapy

Rooted in our commitment to deliver a comprehensive, unparalleled cold tumor treatment platform, ImmunoGenesis is building complementary pipeline programs from the bottom up.

Our pipeline programs directly target several key pathology processes that make cold tumors so difficult to treat.

Our programs

Prime an effective T-cell response

Block checkpoint signals effectively

Address the suppressive tumor microenvironment



Our lead program is IMGS‑001, a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function. This means the molecule can target and kill the immunosuppressive cells in the tumor microenvironment.

Preclinical data showed that IMGS‑001 offered 5 times the response rate in cold tumors than currently available immunotherapies. Additionally, IMGS‑001 can provide a foundation for add-on therapies.


IMGS‑501 is an antibody-conjugated STING agonist transported systemically by our PD-L1/PD-L2 dual-specific inhibitor, allowing greater flexibility in delivery. With IMGS‑501, there is no need for direct tumor injection. The STING agonist can be effectively delivered intravenously to all sites of the tumor and within the tumor microenvironment.

Extension program

Our platform presents opportunities to pair with additional programs. Such programs could include creating tri-functional bispecifics.

Additionally, we’ve extended our program to include the hypoxia-reversal agent evofosfamide. While not our primary target, this hypoxia-reversal agent sensitizes tumors for checkpoint inhibition and is on target to be in clinic in 2022.